AI Article Synopsis
- Long COVID is defined by the WHO as lasting symptoms three months after a COVID-19 infection, affecting about 50 million individuals with no currently effective treatments.
- Recent studies, including case series and randomized trials, have shown that Hyperbaric Oxygen Therapy (HBO) can lead to significant improvements for those suffering from long COVID.
- It’s suggested that HBO is a safe option for treating long COVID symptoms and should be further researched for its potential benefits.
Article Abstract
Background: The World Health Organization defines long COVID as "the continuation or development of new symptoms 3 months after the initial SARS-CoV-2 infection, with these symptoms lasting for at least 2 months with no other explanation." Estimations of approximately 50 million individuals suffer from long COVID, reporting low health-related quality of life. Patients develop ongoing persistent symptoms that continue for more than 12 weeks that are not explained by another alternative diagnosis. To date, no current therapeutics are effective in treating the underlying pathophysiology of long COVID.
Discussion: A comprehensive literature search using PubMed and Google Scholar was conducted and all available articles from November 2021 to January 2024 containing keywords long covid and hyperbaric oxygen were reviewed. These published studies, including case series and randomized trials, demonstrate that utilizing Hyperbaric Oxygen Therapy (HBO) provided significant improvement in patients with long COVID.
Conclusion: A large cohort of patients suffer from long COVID or post-COVID-19 syndrome after recovery from their acute infection with no effective treatment options. HBO is a safe treatment and may provide benefit for this population and should continue to be researched for adjunctive treatment of long COVID.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10916685 | PMC |
| http://dx.doi.org/10.3389/fmed.2024.1354088 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical risk factors of long-term post-traumatic stress symptoms, anxiety, and depression in COVID-19 survivors.
Eur Arch Psychiatry Clin Neurosci
December 2024
CAS Key Laboratory of Mental Health, Institute of Psychology, Beijing, 100101, China.
The COVID-19 pandemic has a profound and lasting impact on the mental health of recovered individuals. To investigate the clinical risk factors associated with long-term post-traumatic stress symptoms (PTSS), anxiety, and depression in COVID-19 survivors, demographic information and medical records were collected during February 19 and March 20, 2020. Assessments of PTSS, anxiety, and depressive symptoms were conducted at two months (April to May 2020, Session 1) and two years (April to May 2022, Session 2) post-discharge.
View Article and Find Full Text PDFSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the virus that caused the Coronavirus Disease 2019 (COVID-19) pandemic, has a spike glycoprotein that is involved in recognizing and fusing to host cell receptors, such as angiotensin-converting enzyme 2 (ACE2), neuropilin-1 (NRP1), and AXL tyrosine-protein kinase. Since the major spike protein receptor is ACE2, an enzyme that regulates angiotensin II (1-8), this study tested the hypothesis that angiotensin II (1-8) influences the binding of the spike protein to its receptors. While angiotensin II (1-8) did not influence spike-ACE2 binding, we found that it significantly enhances spike-AXL binding.
View Article and Find Full Text PDFLong COVID (LC), manifests in 10-30% of non-hospitalized individuals post-SARS-CoV-2 infection leading to significant morbidity. The predictive role of gut microbiome composition during acute infection in the development of LC is not well understood, partly due to the heterogeneous nature of disease. We conducted a longitudinal study of 799 outpatients tested for SARS-CoV-2 (380 positive, 419 negative) and found that individuals who later developed LC harbored distinct gut microbiome compositions during acute infection, compared with both SARS-CoV-2-positive individuals who did not develop LC and negative controls with similar symptomatology.
View Article and Find Full Text PDFHerpes zoster ophthalmicus temporally after COVID-19 vaccination: a systematic review of uncontrolled case reports and case series.
Proc (Bayl Univ Med Cent)
December 2024
College of Medicine, Texas A&M University, Houston, Texas, USA.
Purpose: Herpes zoster ophthalmicus (HZO) following COVID-19 vaccination has been reported previously but the clinical characteristics, onset, treatment, and outcomes of these cases have not been previously systematically reviewed.
Methods: A systematic review, guided by PRISMA guidelines, surveyed PubMed and Embase databases from April 2021 to June 2023 for case reports and series detailing HZO following COVID-19 vaccination. Studies excluded were abstracts, reviews, and clinical trials.
Spatial distribution of SARS-CoV-2 incidence, social inequality, housing conditions, and density in South-Eastern France: keys for future epidemics.
Front Public Health
December 2024
Université Côte d'Azur, Centre Hospitalier Universitaire de Nice, Public Health Department, Nice, France.
Introduction: Early in 2021, the SARS-CoV-2 incidence rate was higher in the East than in the West of the Alpes-Maritimes district in France. What was the impact of social deprivation, household overcrowding and population density per km on this difference in incidence rate?
Methods: Cases were defined as persons with a first SARS-CoV-2 positive test detected between 04/01/2021 and 14/02/2021. We studied the « French Deprivation index » (FDep), rate of overcrowded households and population density/km.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!